Related Experiment Video
Updated: Dec 14, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.2K
[Anticoagulation for Stroke Prevention in Atrial Fibrillation]
Deutsche Medizinische Wochenschrift (1946)
|July 16, 2020
Summary
New oral anticoagulants (NOACs) are preferred for stroke prevention in atrial fibrillation over vitamin K antagonists (VKAs). NOACs offer easier management and reduce bleeding complications, eliminating the need for bridging therapy.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Atrial fibrillation necessitates anticoagulation for stroke prevention.
- Vitamin K antagonists (VKAs) have been the traditional standard of care.
- Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as a preferred alternative.
Purpose of the Study:
- To compare the efficacy and safety of NOACs versus VKAs for stroke prevention in atrial fibrillation.
- To highlight the advantages of NOACs in patient management and procedural care.
Main Methods:
- Guideline recommendations are based on large randomized clinical phase III studies of NOACs.
- Observational studies provide complementary data on NOACs versus VKAs.
- Pharmacokinetic and pharmacodynamic properties of NOACs were considered.
Main Results:
- NOACs are the preferred therapy for stroke prevention in atrial fibrillation.
- VKAs are reserved for specific contraindications like mechanical heart valves.
- NOACs simplify anticoagulation management, especially during therapy interruptions.
- Bridging therapy with heparin is often unnecessary with NOACs, significantly reducing bleeding risks.
Conclusions:
- NOACs represent a significant advancement in anticoagulation therapy for atrial fibrillation.
- The ease of handling and improved safety profile of NOACs lead to better patient outcomes and reduced complications.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
01:29Venous Thrombosis III: Interprofessional Care
189
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
189
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
931
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
931
01:30Venous Thrombosis IV: Nursing Management
138
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
138
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
160
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
160